Abstract
Patients with primary immune thrombocytopenia (ITP) may require treatment to reduce the risk of serious bleeding if platelets remain consistently below 30 × 109/L. While approximately 70–80% of patients respond to an initial course of corticosteroids, relapse is common. For steroid-refractory patients, there is a choice between surgical splenectomy and further medical treatments, based on many factors including the patient’s bleeding history, fitness for surgery, comorbidities, tolerance of adverse events, lifestyle and preferences. Treatments that have traditionally been used (corticosteroids, azathioprine, danazol) suppress the immune system, potentially predisposing patients to infection. Recent insights into the underlying pathophysiology of the disease have allowed the development of targeted therapies, including the thrombopoietin (TPO) receptor agonists, which enhance platelet production. Phase III trials have found romiplostim and eltrombopag to be well tolerated and effective in elevating platelet counts and reducing bleeding in both splenectomised and nonsplenectomised patients with chronic ITP. The B-cell targeted monoclonal antibody rituximab has also shown some potential in this setting, although data are currently limited and there are toxicity concerns. The decision whether to proceed to splenectomy or try other medical therapies in corticosteroid-refractory patients remains patient-specific. Splenectomy has its risks (including perioperative and long-term risks), and relapse/nonresponse are relatively common, but it offers the possibility of cure in the majority of patients. However, newer treatments may potentially allow splenectomy to be deferred for prolonged periods, as well as providing alternative treatment options for patients who fail splenectomy.
Similar content being viewed by others
References
British Committee for Standards in Haematology General Haematology Task Force (2003) Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 120(4):574–596
George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ et al (1996) Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 88(1):3–40
Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB et al (2010) International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 115(2):168–186
Bussel J (2006) Treatment of immune thrombocytopenic purpura in adults. Semin Hematol 43(3 Suppl 5):S3–S10, discussion S8–9
Cines DB, McMillan R (2005) Management of adult idiopathic thrombocytopenic purpura. Annu Rev Med 56:425–442
Stasi R, Stipa E, Masi M, Cecconi M, Scimo MT, Oliva F et al (1995) Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 98(5):436–442
Sailer T, Lechner K, Panzer S, Kyrle PA, Pabinger I (2006) The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy. Haematologica 91(8):1041–1045
Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM et al (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura (ITP) of adults and children: report from an international working group. Blood 113:2386–2393
Hitzrot JM (1923) Splenectomy in hemorrhagic purpura: idiopathic purpura, essential thrombopenie (Frank). Purpura hemorrhagic protopathique (Hayem). Ann Surg 78(2):185–190
Kojouri K, Vesely SK, Terrell DR, George JN (2004) Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 104(9):2623–2634
Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A (2001) Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 97(9):2549–2554
Schwartz J, Leber MD, Gillis S, Giunta A, Eldor A, Bussel JB (2003) Long term follow-up after splenectomy performed for immune thrombocytopenic purpura (ITP). Am J Hematol 72(2):94–98
Naouri A, Feghali B, Chabal J, Boulez J, Dechavanne M, Viala JJ et al (1993) Results of splenectomy for idiopathic thrombocytopenic purpura. Review of 72 cases. Acta Haematol 89(4):200–203
Cortelazzo S, Finazzi G, Buelli M, Molteni A, Viero P, Barbui T (1991) High risk of severe bleeding in aged patients with chronic idiopathic thrombocytopenic purpura. Blood 77(1):31–33
Winslow ER, Brunt LM (2003) Perioperative outcomes of laparoscopic versus open splenectomy: a meta-analysis with an emphasis on complications. Surgery 134(4):647–653, discussion 54–5
Crary SE, Buchanan GR (2009) Vascular complications after splenectomy for hematologic disorders. Blood 114(14):2861–2868
Vianelli N, Galli M, de Vivo A, Intermesoli T, Giannini B, Mazzucconi MG et al (2005) Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases. Haematologica 90(1):72–77
Bell WR Jr (2000) Long-term outcome of splenectomy for idiopathic thrombocytopenic purpura. Semin Hematol 37(1 Suppl 1):22–25
Najean Y, Rain JD, Billotey C (1997) The site of destruction of autologous 111In-labelled platelets and the efficiency of splenectomy in children and adults with idiopathic thrombocytopenic purpura: a study of 578 patients with 268 splenectomies. Br J Haematol 97(3):547–550
Law C, Marcaccio M, Tam P, Heddle N, Kelton JG (1997) High-dose intravenous immune globulin and the response to splenectomy in patients with idiopathic thrombocytopenic purpura. N Engl J Med 336(21):1494–1498
Bussel JB, Kaufmann CP, Ware RE, Woloski BM (2001) Do the acute platelet responses of patients with immune thrombocytopenic purpura (ITP) to IV anti-D and to IV gammaglobulin predict response to subsequent splenectomy? Am J Hematol 67(1):27–33
Bell WR Jr (2002) Role of splenectomy in immune (idiopathic) thrombocytopenic purpura. Blood Rev 16(1):39–41
George JN (2006) Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost 4(8):1664–1672
McMillan R, Durette C (2004) Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood 104(4):956–960
George JN, Mathias SD, Go RS, Guo M, Henry DH, Lyons R et al (2009) Improved quality of life for romiplostim-treated patients with chronic immune thrombocytopenic purpura: results from two randomized, placebo-controlled trials. Br J Haematol 144(3):409–415
Davies JM, Barnes R, Milligan D (2002) Update of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Clinical Medicine 2(5):440–443, London, England
Makris M, Greaves M, Winfield DA, Preston FE, Lilleyman JS (1994) Long-term management after splenectomy. Lifelong penicillin unproved in trials. BMJ 308(6921):131–132, Clinical research ed
El-Alfy MS, El-Sayed MH (2004) Overwhelming postsplenectomy infection: is quality of patient knowledge enough for prevention? Hematol J 5(1):77–80
Rodeghiero F, Ruggeri M (2008) Is splenectomy still the gold standard for the treatment of chronic ITP? Am J Hematol 83(2):91
Dorner T, Burmester GR (2008) New approaches of B-cell-directed therapy: beyond rituximab. Curr Opin Rheumatol 20(3):263–268
George JN, Kojouri K, Perdue JJ, Vesely SK (2000) Management of patients with chronic, refractory idiopathic thrombocytopenic purpura. Semin Hematol 37(3):290–298
Branehog I, Kutti J, Weinfeld A (1974) Platelet survival and platelet production in idiopathic thrombocytopenic purpura (ITP). Br J Haematol 27(1):127–143
Branehog I, Weinfeld A (1974) Platelet survival and platelet production in idiopathic thrombocytopenic purpura (ITP) before and during treatment with corticosteroids. Scand J Haematol 12(1):69–79
Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM et al (2008) Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet 371(9610):395–403
Arkfeld DG (2008) The potential utility of B cell-directed biologic therapy in autoimmune diseases. Rheumatol Int 28(3):205–215
Kaushansky K (1995) Thrombopoietin: the primary regulator of platelet production. Blood 86(2):419–431
Wang B, Nichol JL, Sullivan JT (2004) Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 76(6):628–638
Newland A, Caulier MT, Kappers-Klunne M, Schipperus MR, Lefrere F, Zwaginga JJ et al (2006) An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 135(4):547–553
Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT et al (2006) AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 355(16):1672–1681
Basser RL, O'Flaherty E, Green M, Edmonds M, Nichol J, Menchaca DM et al (2002) Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 99(7):2599–2602
Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M et al (2001) Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98(12):3241–3248
Nplate® Summary of Product Characteristics. Available at: http://www.ema.europa.eu/humandocs/PDFs/EPAR/nplate/emea-combined-h942en.pdf. Last accessed 21 Apr 2010
Bussel JB, Kuter DJ, Pullarkat V, Lyons RM, Guo M, Nichol JL (2009) Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. Blood 113(10):2161–2171, Erratum in: Blood. 2009;113:4822
Bussel JB, Kuter DJ, Newland A, de Wolf JTM, Wasser J, Chang P et al (2009) Long-term efficacy and safety of romiplostim for the treatment of patients with chronic immune thrombocytopenia (ITP): 5-year update from an open-label extension study. ASH 114(22):681, Annual Meeting Abstracts
Gernsheimer TB, George JN, Aledort LM, Tarantino MD, Sunkara U, Matthew Guo D, Nichol JL (2010) Evaluation of bleeding and thrombotic events during long-term use of romiplostim in patients with Chronic Immune Thrombocytopenia (ITP). J Thromb Haemost. 8(6):1372–1382
Kuter DJ, Bain B, Mufti G, Bagg A, Hasserjian RP (2007) Bone marrow fibrosis: pathophysiology and clinical significance of increased bone marrow stromal fibres. Br J Haematol 139(3):351–362
Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B et al (2007) Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 357(22):2237–2247
Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D et al (2007) Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 109(11):4739–4741
Revolade Summary of Product Characteristics Available at: http://www.ema.europa.eu/humandocs/PDFs/EPAR/revolade/emea-combined-h1110en.pdf. Last accessed 26 May 2010
Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L et al (2009) Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 373(9664):641–648
Bussel J, Cheng G, Saleh M, Meddeb B, Stone A, Mayer B et al (2008) Long-term safety and efficacy of oral eltrombopag for the treatment of idiopathic thrombocytopenic purpura (ITP). Haematologia 93(S1):949
Cheng G, Saleh MN, Bussel JB, Marcher C, Vasey S, Mayer B et al (2008) Oral eltrombopag for the long-term treatment of patients with chronic idiopathic thrombocytopenic purpura: Results of a Phase III, Double- Blind, Placebo-Controlled Study (RAISE). ASH Annual Meeting Abstracts. 112(11):400
Mabthera Summary of Product Characteristics 2008. Available at: http://www.ema.europa.eu/humandocs/PDFs/EPAR/Mabthera/emea-combined-h165en.pdf. last accessed: 1 Mar 2010
Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C et al (2007) Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 146(1):25–33
Hasan A, Michel M, Patel V, Stasi R, Cunningham-Rundles S, Leonard JP et al (2009) Repeated courses of rituximab in chronic ITP: three different regimens. Am J Hematol 84(10):661–665
Zaja F, Baccarani M, Mazza P, Bocchia M, Gugliotta L, Zaccaria A et al (2010) Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 115(14):2755–2762
Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF et al (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. Blood 113(20):4834–4840
US Food and Drug Administration. Information for Healthcare Professionals: Rituximab (marketed as Rituxan). Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109106.htm. 2006
Provan D, Butler T, Evangelista ML, Amadori S, Newland AC, Stasi R (2007) Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica 92(12):1695–1698
Zaja F, Battista ML, Pirrotta MT, Palmieri S, Montagna M, Vianelli N et al (2008) Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica 93(6):930–933
Podolanczuk A, Lazarus AH, Crow AR, Grossbard E, Bussel JB (2009) Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 113(14):3154–3160
Li X, Hou M (2008) Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs 13(2):237–254
Watson-Williams EJ, Macpherson AI, Davidson S (1958) The treatment of idiopathic thrombocytopenic purpura; a review of 93 cases. Lancet 2(7040):221–226
Todorovic-Tirnanic M, Obradovic V, Rolovic Z, Suvajdzic N, Elezovic I, Colovic M et al (2005) Prediction of the splenectomy efficacy in chronic immune thrombocytopenic purpura. Glas Srpska akademija nauka i umetnosti 48:119–135
von dem Borne AE, Vos JJ, Pegels JG, Thomas LL, van der Lilie H (1988) High dose intravenous methylprednisolone or high dose intravenous gammaglobulin for autoimmune thrombocytopenia. Br Med J 296(6617):249–250, Clinical research ed
Kuku I, Aydogdu I, Kaya E, Ali Erkurt M, Dikilitas M, Baydar M et al (2005) The early and long-term results of oral high-dose methylprednisolone treatment in adult patients with idiopathic thrombocytopenic purpura. Eur J Haematol 74(3):271–272
Cheng Y, Wong RS, Soo YO, Chui CH, Lau FY, Chan NP et al (2003) Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 349(9):831–836
Stasi R, Brunetti M, Pagano A, Stipa E, Masi M, Amadori S (2000) Pulsed intravenous high-dose dexamethasone in adults with chronic idiopathic thrombocytopenic purpura. Blood Cells Mol Dis 26(6):582–586
Talar-Williams C, Sneller MC (1994) Complications of corticosteroid therapy. Eur Arch Otorhinolaryngol 251(3):131–136
Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B et al (1994) Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 96(2):115–123
Aledort LM, Hayward CP, Chen MG, Nichol JL, Bussel J (2004) Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies. Am J Hematol 76(3):205–213
Amgen Inc. Nplate Prescribing information. Available at: http://www.nplatenexus.com/pdfs/misc/nplate_pi.pdf. Last accessed 3 May 2010. 2008
GlaxoSmithKline. Promacta Prescribing Information. http://us.gsk.com/products/assets/us_promacta.pdf. Last accessed 3 May 2010. 2009
Patel V, Mihatov N, Cooper N, Stasi R, Cunningham-Rundles S, Bussel JB (2006) Long Term Follow-Up of Patients with Immune Thrombocytopenic Purpura (ITP) Whose Initial Response to Rituximab Lasted a Minimum of 1 Year. ASH Annual Meeting Abstracts. 2006 November 16, 108(11):479
Adams JR, Nathan DP, Bennett CL (2002) Pharmacoeconomics of therapy for ITP: steroids, i.v.Ig, anti-D, and splenectomy. Blood Rev 16(1):65–67
Stasi R, Evangelista ML, Stipa E, Buccisano F, Venditti A, Amadori S (2008) Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost 99(1):4–13
Sandoglobulin Summary of Product Characteristics 2008. Available at: http://emc.medicines.org.uk/medicine/15934/SPC/Sandoglobulin+NF+Liquid%2c+120+mg+ml+solution+for+infusion/. Last accessed 08 Apr 09
D-Gam Summary of Product Characteristics 2008. Available at: http://emc.medicines.org.uk/medicine/14735/SPC/D-GAM%2c+Solution+for+Injection+1%2c500+and+2%2c500iu+vials/. Last accessed: 21 Apr 2010
WinRHO Summary of Product Characteristics. 2008. Available at: http://www.ecomm.baxter.com/ecatalog/loadResource.do?bid=39462 last accessed: 8 Apr 2009
George JN, Buchanan G. ITP Support association platelet reprint series. Available at: http://www.itpsupport.org.uk/american
Risks and complications of surgery 2007. Available at: accessed at: http://generalmedicine.suite101.com/article.cfm/risks_and_complications_of_surgery; last accessed: 13 May 2009
Schilling RF (1997) Spherocytosis, splenectomy, strokes, and heat attacks. Lancet 350(9092):1677–1678
Jais X, Ioos V, Jardim C, Sitbon O, Parent F, Hamid A et al (2005) Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax 60(12):1031–1034
Robinette CD, Fraumeni JF Jr (1977) Splenectomy and subsequent mortality in veterans of the 1939–45 war. Lancet 2(8029):127–129
Kumagai Y, Fujita T, Ozaki M, Sahashi K, Ohkura M, Ohtsu T et al (2007) Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study. J Clin Pharmacol 47(12):1489–1497
Glaxosmithkline Ltd. Promacta FDA ODAC briefing document 2008
Bouroncle BA, Doan CA (1966) Refractory idiopathic thrombocytopenic purpura treated with azathioprine. N Engl J Med 275(12):630–635
Quiquandon I, Fenaux P, Caulier MT, Pagniez D, Huart JJ, Bauters F (1990) Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. Br J Haematol 74(2):223–228
Sussman LN (1967) Azathioprine in refractory idiopathic thrombocytopenic purpura. Jama 202(4):259–263
Finch SC, Castro O, Cooper M, Covey W, Erichson R, McPhedran P (1974) Immunosuppressive therapy of chronic idiopathic thrombocytopenic purpura. Am J Med 56(1):4–12
Reiner A, Gernsheimer T, Slichter SJ (1995) Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood 85(2):351–358
Srichaijul T, Boonpucknavig S, Archararit N, Chaisiri-pumkeeree W (1980) Chronic immunologic thrombocytopenic purpura: results of cyclophosphamide therapy before splenectomy. Arch Intern Med 140(5):636–638
Verlin M, Laros RK Jr, Penner JA (1976) Treatment of refractory thrombocytopenic purpura with cyclophosphamine. Am J Hematol 1(1):97–104
Krause JR (1982) Chronic idiopathic thrombocytopenic purpura (ITP:) development of acute non-lymphocytic leukemia subsequent to treatment with cyclophosphamide. Med Pediatr Oncol 10(1):61–65
Emilia G, Messora C, Longo G, Bertesi M (1996) Long-term salvage treatment by cyclosporin in refractory autoimmune haematological disorders. Br J Haematol 93(2):341–344
Kappers-Klunne MC, van’t Veer MB (2001) Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol 114(1):121–125
Maloisel F, Andres E, Zimmer J, Noel E, Zamfir A, Koumarianou A et al (2004) Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med 116(9):590–594
Vancine-Califani SM, De Paula EV, Ozelo MC, Orsi FL, Fabri DR, Annichino-Bizzacchi JM (2008) Efficacy and safety of dapsone as a second-line treatment in non-splenectomized adults with immune thrombocytopenic purpura. Platelets 19(7):489–495
Fanello CI, Karema C, Avellino P, Bancone G, Uwimana A, Lee SJ et al (2008) High risk of severe anaemia after chlorproguanil-dapsone+artesunate antimalarial treatment in patients with G6PD (A-) deficiency. PLoS ONE 3(12):e4031
Provan D, Moss AJ, Newland AC, Bussel JB (2006) Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol 81(1):19–25
Szczepanik AB, Sikorska A, Slomkowski M, Konopka L (2007) The use of vinca alkaloids in preparation for splenectomy of corticosteroid refractory chronic immune thrombocytopenic purpura patients. Int J Lab Hematol 29(5):347–351
Acknowledgements
This article is based on a debate between the authors, which took place in Berlin, Germany on June 4th 2009 during the 14th European Haematology Association Congress and was supported by Amgen Europe GmbH, Zug, Switzerland. The authors thank Julia Balfour, Medical Writer, Kilconquhar, Scotland for assistance with the preparation of the manuscript, with financial support from Amgen.
Conflicts of interest disclosures
Authors conflict of interest declarations are as follows: Prof. Newland—Research funding from Amgen, Baxter, GSK and Genentech; consultant and speaker for Amgen and GSK; advisory board for GSK and Pangenetics; Dr. Stasi—advisory boards and/or speaker for GSK and Amgen. Dr. Pabinger—speaker and advisory boards for Amgen and GSK. Dr. Thornton has no conflicts of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stasi, R., Newland, A., Thornton, P. et al. Should medical treatment options be exhausted before splenectomy is performed in adult ITP patients? A debate. Ann Hematol 89, 1185–1195 (2010). https://doi.org/10.1007/s00277-010-1066-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-010-1066-2